Clinical Trial Update: ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial updates on a CD8-targeted PET tracer 89Zr-Df-IAB22M2C for PET/CT in patients with metastatic solid tumors, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• 89Zr-Df-IAB22M2C (CD8 PET tracer) (89Zr-Df-IAB22M2C)

Snippet

Sponsor: ImaginAb, Inc. | Conditions: Positron-Emission Tomography, Metastatic Solid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2024-07-09